• 1. Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing 100010, P.R.China;
  • 2. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union, Beijing 100021, P.R.China;
  • 3. Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R.China;
  • 4. Beijing Institute of Traditional Chinese Medicine, Beijing 100010, P.R.China;
  • 5. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, P.R.China;
  • 6. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P.R.China;
  • 7. School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, P.R.China;
  • 8. Chinese EQUATOR Centre, Hong Kong 999077, P.R.China;
DUAN Yuting, Email: shanghongcai@foxmail.com; BIAN Zhaoxiang, Email: bianzxiang@gmail.com
Export PDF Favorites Scan Get Citation

背景  單病例隨機對照試驗是評價中醫藥干預措施有效性和安全性較為理想和適宜的方法之一。目前已有一定數量的中醫藥單病例隨機對照試驗發表。然而,由于缺乏相應的報告規范,這些試驗的報告質量普遍較差。鑒于中醫藥臨床研究的獨特性,工作組制定了單病例隨機對照試驗報告標準(CONSORT extension for reporting N-of-1 trials,CENT 2015)的中醫藥擴展版(中醫藥 CENT),以幫助研究者報告中醫藥單病例試驗。 方法  我們在提高健康研究質量和透明度協作網(Enhancing the QUAlity and Transparency Of health Research,EQUATOR)上注冊了中醫藥 CENT。中醫藥單病例隨機對照試驗報告規范的制定是一個綜合過程,包括收集初始報告條目,與 17 名專家小組成員進行兩輪科學的德爾菲共識調查,修訂和形成最終報告清單。 結果  清單共包括 6 個領域的 25 項條目,其中的 8 項對 CENT 2015 清單條目進行了擴展和詳細說明。中醫藥 CENT 清單充分考慮了中醫藥的診療特點,并詳細闡釋了中醫藥單病例隨機對照試驗中辨證的概念和不同的中醫藥干預措施。 結論  中醫藥 CENT 是中醫臨床研究的一個實用工具,可用于評價中醫藥單病例對照試驗報告的完整性,并可指導中醫藥單病例對照試驗的設計、實施和報告,期望此報告規范可切實提高中醫藥單病例試驗的全面性和透明度。

Citation: Translated by HU Jiayuan, LI Jiang, ZHAI Jingbo, LI Bo, TIAN Jinhui, MA Bin, YANG Kehu, DAI Min, TIAN Guihua, SHANG Hongcai, ZHANG Chi, DUAN Yuting, BIAN Zhaoxiang. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): recommendations, explanation and elaboration. Chinese Journal of Evidence-Based Medicine, 2021, 21(3): 338-346. doi: 10.7507/1672-2531.202008173 Copy

Copyright ? the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved

  • Previous Article

    CONSORT 2010 statement: extension to randomised pilot and feasibility trials
  • Next Article

    Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension